جستجوی مقالات مرتبط با کلیدواژه « sox9 » در نشریات گروه « پزشکی »

Aldehyde dehydrogenase 1 (ALDH1) is an enzyme accountable for the detoxification of aldehydes. Sex-determining region Y-box 9 (SOX-9) plays a role in many biological and pathological processes. In this study, we aimed to evaluate the prognostic significance of ALDH1 and SOX9 expression in early breast cancer.
The expression of ALDH1 and SOX-9 was evaluated through immunohistochemistry derived from 50 eligible patients with early breast cancer included in the current prospective cohort study.
Positive expression of ALDH1 and SOX-9 were detected in 29 (58%) and 34 (68%) patients, respectively. The positive expressions of both markers were statistically significant associated with increasing the stage, lymph nodes metastasis, high Ki67 labeling index, and molecular subtypes (P < 0.001), along with with the biological markers; estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 over-expressions, and large tumor size (P = 0.039, P = 0.022, P = 0.024 and P = 0.003 for ALDH1 expression and P = 0.012, P = 0.007, P = 0.004 , and P = 0.002 for SOX-9 expression, respectively). There is a significant positive association between the expression of ALDH1 and SOX-9, r (correlation coefficient) = +0.806 (P < 0.001). Local recurrence was associated with the positive expression of ALDH1 only (P = 0.045) and the disease progression was statistically significant and associated with the positive expression of both ALDH1 and SOX-9 (P = 0.038, P = 0.023, respectively). There was significant association of positive expression of SOX-9 with reduced 3-y disease-free survival (P = 0.039).
Positive expression of ALDH-1 and SOX9 were associated with aggressive histopathological features and poor outcome in early breast cancer and can be considered potential prognostic markers in this group of patients.

So far, many studies have been conducted on the importance of expressing different genes in humans and zebrafish. In this regard, the expression of OCT4, HOX and SOX genes as influential genes in the embryonic period is very thought-provoking. At different embryonic stages, including morula, middle blastula, gastrula, and segmentation, the expression of these genes is very important in the growth, immunity, tissue repair, and viability of different cells. The aim of this study was to investigate the expression of common genes between humans and zebrafish in the embryonic period and their efficiency in different parts of the body.

Prostate cancer (PCa) is the second leading cause of cancer death in men, worldwide. Geranylgeranylation and farnesylation have a main role in the carcinogenic process, which can be prevented via statins as HMGCOA reductase enzyme inhibitors in cholesterol biosynthesis. These effects might be controlled by several transcription factors such as SOX7 and SOX9, which have been involved in PCa initiation and progression. To the best of our knowledge, no study has demonstrated the association of simvastatin and SOX status in PCa. Therefore, this study is an attempt to evaluate whether simvastatin induces anti-neoplastic effects via the SOX9 and SOX7 transcription factors. Prostate cancer cell lines LNCaP and PC3 were used to evaluate the expression of SOX7 and SOX9 using quantitative RT-PCR. Our data was analyzed by applying one-way ANOVA and Tukey's test and determined that 0.07 µM of simvastatin after 24 h was sufficient to upregulate SOX7 mRNA expression ratio by 3.58 fold in LNCaP. In addition, the level of SOX9 mRNA expression was increased by 12.18 fold at 0.07 µM after 24 h, 8.67 fold at 0.001 µM after 24 h, and 6.33 fold at 0.07 µM after 12 h in LNCaP and in PC3 cell line. The level of SOX9 mRNA expression was increased by 2.64 fold at 0.5 µM after 24 h and 2.78 fold at 0.1 µM after 12 h, however, it decreased by 0.67 fold at 0.1 µM after 24 h. Our findings suggest that simvastatin can induce the anti-cancer properties via manipulating the expression of SOX7 in LNCaP, as the androgen-dependent cell.

SOX9 is a transcriptional activator which is necessary for chondrogenesis. SOX6 are closely related to DNA-binding proteins that critically enhance its function. Therefore, to carry out the growth plate chondrocyte differentiation program, SOX9 and SOX6 collaborate genomewide. Chondrocyte differentiation is also known to be promoted by glucocorticoids through unknown molecular mechanisms. We investigated the effects of asynthetic glucocorticoid, dexamethasone (DEX), on SOX9 gene expression in chondrocytes. SOX9 mRNA was expressed at high levels in these chondrocytes. Treatment with DEX resulted in enhancement of SOX9 mRNA expression. The DEX effect was dose dependent (0·5 nM and 1 nM). RT-PCR analysis revealed that DEX also enhanced the levels of SOX9 expression. It was observed that DEX had enhancing effect only on SOX9 the expression level was low for SOX6. It can thus be concluded that chondrocyte differentiation can be promoted by DEX via SOX9 enhancement.